Your browser doesn't support javascript.
loading
Hepatic Steatosis Associated With Exposure to Elvitegravir and Raltegravir.
Kirkegaard-Klitbo, Ditte Marie; Thomsen, Magda Teresa; Gelpi, Marco; Bendtsen, Flemming; Nielsen, Susanne Dam; Benfield, Thomas.
Affiliation
  • Kirkegaard-Klitbo DM; CREDID, Department of Infectious Diseases, Copenhagen University Hospital, Amager and Hvidovre, Hvidovre, Denmark.
  • Thomsen MT; Viro-immunology Research Unit, Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Gelpi M; Viro-immunology Research Unit, Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Bendtsen F; Gastrounit, Medical Division, Copenhagen University Hospital, Amager and Hvidovre, Hvidovre, Denmark.
  • Nielsen SD; Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Benfield T; Viro-immunology Research Unit, Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Clin Infect Dis ; 73(3): e811-e814, 2021 08 02.
Article in En | MEDLINE | ID: mdl-33493297
ABSTRACT
Moderate-to-severe hepatic steatosis in people living with human immunodeficiency virus (HIV) without viral hepatitis or excessive alcohol intake was associated with cumulative exposure to stavudine, elvitegravir, and raltegravir. Prospective trials are required to establish a causal association. Clinical Trials Registration. NCT02382822.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: HIV Infections / Quinolones Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: En Year: 2021 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: HIV Infections / Quinolones Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: En Year: 2021 Type: Article